Open Access

Burden of Type 2 Diabetes from the Healthcare Payer Perspective in Slovenia / Breme Sladkorne Bolezni Tipa 2 S Stališča Plačnika Zdravstvenega Varstva V Sloveniji


1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.10.1016/j.diabres.2009.10.00719896746Search in Google Scholar

2. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 293-301.10.1016/j.diabres.2010.01.02620171754Search in Google Scholar

3. Jelić J, Drinovec J, Mrhar A. Burden of type 2 diabetes. Farm vest 2006; 5: 316-324.Search in Google Scholar

4. Nacionalni program za obvladovanje sladkorne bolezni, strategija razvoja 2010 - 2020, November 2009. Available October 15, 2011 from: diabetes/Nacionalni_program_obvladovanja_sladkorne_ bolezni_210410.pdfSearch in Google Scholar

5. Slovenian public healtcare expenditures plan for 2011. Available October 27, 2011 from: in Google Scholar

6. Enotni seznam zdravstvenih storitev in samoupravni sporazum o njegovi uporabi v svobodni menjavi dela (Greenbook). Ljubljana, 1982.Search in Google Scholar

7. General agreement for the contract year 2010. Občasnik ZZZS. Available October 26, 2011 from:$FILE/Ob%C4%8Dasnik%20Akti%20&%20navodila_1.%20del_03.05.2010.pdfSearch in Google Scholar

8. General agreement for the contract year 2010: design and financing of health services for natural health resorts. Občasnik ZZZS. Available October 30, 2011 from:$FILE/Ob%C4%8Dasnik%20Akti%20&%20navodila_2.%20del_03.05.2010.pdfSearch in Google Scholar

9. Average healthcare prices, from 1.10.2011 on, ZZZS, Ljubljana, 2011. Available October 10, 2011 from: in Google Scholar

10. Slovenian National Institute of Public Health, Sheet T13 (Number of acute healtcare events grouped by Diagnosis related groups - DRG in 2009). Available October 15, 2011 from: in Google Scholar

11. Data from The Health Insurance Institute of Slovenia outpatient drug dispense database from the year 2008.Search in Google Scholar

12. Slovenian medicine costs on the day 14.10.2011. JAZMP. Available October 15, 2011 from: in Google Scholar

13. Slovenian National Institute of Public Health. Drug consume database from 2001 to 2010. Available October 11, 2011 from: in Google Scholar

14. The Health Insurance Institute of Slovenia, Medical technical devices database. Available April 24, 2012 from:$FILE/SEZNAM%20S%20%C5%A0IFRANTOM,MK,POSTOPKI,CS,%201.3.2012.xlsSearch in Google Scholar

15. The Health Insurance Institute of Slovenia business report 2011. Available April 24, 2012 from:$FILE/Poslovno%20poro%C4%8Dilo%20ZZZS%20za%20leto%202011_19.4.2012.pdfSearch in Google Scholar

16. Yeaw J, Lee WC, Aagren M, Christensen T. Cost ofselfmonitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. J Manag Care Pharm 2012; 18: 21-32.10.18553/jmcp.2012.18.1.2122235952Search in Google Scholar

17. U.S. Renal Data System, USRDS 2008 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.Search in Google Scholar

18. (The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the resposibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.)Search in Google Scholar

19. Postma MJ, de Zeeuw D. The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2009; 10: 2975-2983.Search in Google Scholar

20. ParraMoncasi E, Arenas Jiménez MD, Alonso M et al. Multicentre study of haemodialysis costs. Nefrologia 2011; 31: 299-307.Search in Google Scholar

21. Villa G, Rodríguez-Carmona A, Fernández-Ortiz L et al. Cost analysis of the Spanish renal replacement therapy programme. Nephrol Dial Transplant 2011; 26: 3709-3714.10.1093/ndt/gfr08821427072Search in Google Scholar

22. Haller M, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant 2011; 26: 2988-2995.10.1093/ndt/gfq78021310740Search in Google Scholar

23. Blotière PO, Tuppin P, Weill A, Ricordeau P, Allemand H. The cost of dialysis and kidney transplantation in France in 2007, impact of an increase of peritoneal dialysis and transplantation. Nephrol Ther 2010; 6: 240-247.10.1016/j.nephro.2010.04.00520554257Search in Google Scholar

24. Tan ML, Feng J, Gordois A, Wong ES. Lower extremity amputation prevention in Singapore: economic analysis of results. Simgapore Med J 2011; 52: 662-668.Search in Google Scholar

25. Davis WA, Norman PE, Bruce DG, Davis TM. Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the fremantle diabetes study. Diabetologia 2006; 49: 2634-2641.10.1007/s00125-006-0431-017001469Search in Google Scholar

26. O’Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003; 21: 7.10.1186/1472-6963-3-715353312659641Search in Google Scholar

27. Clarke PM, Glasziou P, Patel A, Chalmers J, Woodward M, Harrap SB, Salomon JA. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med 2010; 7: e10000236.10.1371/journal.pmed.1000236282637920186272Search in Google Scholar

28. Szmurło D, Schubert A, Kostrzewska K, Ryś P, Skrzekowska- Baran I. Economic analysis of the implementation of guidelines for type 2 diabetes control developed by Diabetes Poland: what increase in costs is justified by clinical results? Pol Arch Med Wewn 2011; 121: 345-350.Search in Google Scholar

29. Heerey A, McGowan B, Ryan M, Barry M. Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation. Expert Rev Pharmacoecon Outcomes Res 2002; 2: 29-33.10.1586/14737167.2.1.2919807427Search in Google Scholar

30. Tiemann O. Variations in hospitalisation costs for acute myocardial infarction - a comparison across Europe. Health Econ 2008; 17: S33-S45.10.1002/hec.132218186036Search in Google Scholar

31. Christensen MC, Previgliano I, Capparelli FJ, Lerman D, Lee WC, Wainsztein NA. Acute treatment costs of intracerebral hemorrhage and ischemic stroke in Argentina. Acta Neurol Scand 2009; 119: 246-253.10.1111/j.1600-0404.2008.01094.x18771525Search in Google Scholar

32. Luengo-Fernandez R, Gray AM, Rothwell PM. Costs of stroke using patient-level data: a critical review of the literature. Stroke 2009; 40: e18-e23.10.1161/STROKEAHA.108.52977619109540Search in Google Scholar

33. Thijs V, Dewilde S, Putman K, Pince H. Cost of hospitalization for cerebrovascular disorders in Belgium. Acta Neurol Belg; 2011; 111: 104-110.Search in Google Scholar

34. Truelsen T, Ekman M, Boysen G. Cost of stroke in Europe. Eur J Neurol 2005; 12: 78-84.10.1111/j.1468-1331.2005.01199.x15877785Search in Google Scholar

35. Frier BM. The economic costs of hypoglycaemia. Br J Diabetes Vasc Dis 2011; 11: S10-S12.10.1177/1474651410377558Search in Google Scholar

36. Tenerz A, Lönnberg I, Berne C, Nilsson G, Leppert J. Myocardial infarction and prevalence of diabetes mellitus. Is increased casual blood glucose at admission a reliable criterion for the diagnosis of diabetes? Eur Heart J 2001; 22: 1102-1110.Search in Google Scholar

37. Slovenian National Institute of Public Health, Sheet tb3 (Number of deaths grouped by International Classification of Diseases - ICD in 2009). Available October 12, 2011 from: in Google Scholar

38. Maple-Brown L, Cunningham J, Dunne K, Whitbread C, Howard D, Weeramanthri T, et al. Complicationsof diabetes in urban Indigenous Australians: the DRUID study. Diabetes Res Clin Pract 2008; 80: 455-462.10.1016/j.diabres.2008.01.01118294723Search in Google Scholar

39. Buturović-Ponikar J, Adamlje T, Arnol M, Blanusa D, Ceglar Z, Cimerman-Steklasa S et al. Hemodialysis in Slovenia - data from the Slovenian renal replacement therapy registry. Ther Apher Dial 2010; 14: A1-A15.Search in Google Scholar

40. Kandus A, Arnol M, Kovac D. Forty years of renal transplantation in Slovenia. Ther Apher Dial 2010; 14: A1-A15.Search in Google Scholar

41. Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 2008; 23; 1216-1223.10.1093/ndt/gfn08218359872Search in Google Scholar

42. Sloan FA, Bethel MA, Lee PP, Brown DS, Feinglos MN. Adherence to guidelines and its effects on hospitalizations with complications of type 2 diabetes. Rev Diabet Stud 2004; 1: 29-38.10.1900/RDS.2004.1.29178353017491662Search in Google Scholar

43. Buturović-Ponikvar J et al. Slovenian renal replacement therapy registry: 2006 annual report. Ljubljana: Slovenian Society of Nephrology, 2008.Search in Google Scholar

44. Ponikvar R, Buturović-Ponikvar J. Dializno zdravljenje. Ljubljana: Klinični oddelek za nefrologijo, SPS Interna klinika, Klinični center Ljubljana, 2004.Search in Google Scholar

45. Grego K, Arnol M, Bren AF, Kmetec A, Tomažič J, Kandus A. Basiliximab versus Daclizumab combined with triple immunosuppression in deceased donor renal Graft recipients. Transplant Proc 2007; 39: 3093-3097.10.1016/j.transproceed.2007.04.03218089329Search in Google Scholar

46. Kissela BM, Khoury J, Kleindorfer D, Woo D, Schneider A, Alwell K, Miller R, et al. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care 2005; 28: 355-359.10.2337/diacare.28.2.35515677792Search in Google Scholar

47. G. Veninšek. Diabetes management in Celje general hospital. Zdrav Vest 2001; 70: 7-10.Search in Google Scholar

48. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008; 88: 1254-1264.10.2522/ptj.20080020387032318801858Search in Google Scholar

49. V. Urbančič. Diabetic foot. Maribor: 3. Congress of family medicine, 2004.Search in Google Scholar

50. Novo A, Jokić I. Medical audit of diabetes mellitus in primary care setting in Bosnia and Herzegovina. Croat Med J 2008; 49: 757-762.10.3325/cmj.2008.49.757262103719090600Search in Google Scholar

51. Dejager S, Schweizer A. Minimizing the risk of hypoglycemia with vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Ther 2011; 2: 51-66.10.1007/s13300-010-0018-0314476922127800Search in Google Scholar

52. Globočnik-Petrovič M, Urbančič M, Sevšek D. Smernice za presejanje in zdravljenje diabetične retinopatije. Zdrav Vestn 2010; 79: I7-I18.Search in Google Scholar

53. Rosenberg JB, Friedman IB, Gurland JE. Compliance with screening guidelines for diabetic retinopathy in a large academic children‘s hospital in the Bronx. J Diabetes Complications 2011; 25: 222-226.10.1016/j.jdiacomp.2010.11.00121177125Search in Google Scholar

54. Singh P, Aronow WS, Mellana WM, Gutwein AH. Prevalence of appropriate management of diabetes mellitus in an academic general medicine clinic. Am J Ther 2010; 17: 42-45.10.1097/MJT.0b013e3181822e7819262367Search in Google Scholar

55. Fera T, Bluml BM, Ellis WM, Schaller CW, Garrett DG. The diabetes ten city challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program. J Am Pharm Assoc 2008; 48: 181-190.10.1331/JAPhA.2008.0716618359731Search in Google Scholar

56. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta- analysis. Diabetes Care 2001; 24: 1069-1078.10.2337/diacare.24.6.106911375373Search in Google Scholar

57. Rubin RR, Ciechanowski P, Egede LE, Lin EH, Lustman PJ. Recognizing and treating depression in patients with diabetes. Curr Diab Rep 2004; 4: 119-125.10.1007/s11892-004-0067-815035972Search in Google Scholar

58. Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, Gordois A, Davey P, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005; 21: 1617-1629.10.1185/030079905X6534916238902Search in Google Scholar

59. Jönsson B; CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002; 45: S5-S12.10.1007/s00125-002-0858-x27942782Search in Google Scholar

60. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008; 31: 596-615.10.2337/dc08-901718308683Search in Google Scholar

61. Ballesta M, Carral F, Olveira G, Girón JA, Aguilar M. Economic cost associated with type II diabetes in Spanish patients. Eur J Health Econ 2006; 7: 270-275.10.1007/s10198-006-0367-916850331Search in Google Scholar

62. Nadathur S, Groom A. Codingand DRG relationships in stroke and transientischaemic attack (TIA). HIM J 2006; 35: 38-44.10.1177/18333583060350010618216408Search in Google Scholar

63. The Health Insurance Institute of Slovenia. Compulsory health insurance rules. Available September 17, 2012 from: in Google Scholar

Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Hygiene and Environmental Medicine